170 related articles for article (PubMed ID: 36895178)
21. Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.
Dizdar L; Oesterwind KA; Riemer JC; Werner TA; Mersch S; Möhlendick B; Schütte SC; Verde PE; Raba K; Topp SA; Stoecklein NH; Esposito I; Knoefel WT; Krieg A
Oncotarget; 2017 Jan; 8(5):8369-8382. PubMed ID: 28039474
[TBL] [Abstract][Full Text] [Related]
22. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
[TBL] [Abstract][Full Text] [Related]
23. Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis.
Krieg S; Roderburg C; Fung S; Luedde T; Knoefel WT; Krieg A
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2235-2246. PubMed ID: 35428913
[TBL] [Abstract][Full Text] [Related]
24. [Gastroenteropancreatic neuroendocrine tumors : (GEP-NENs)].
Sebesta C; Feichter A; Selimi F
Wien Med Wochenschr; 2023 Jun; 173(9-10):221-226. PubMed ID: 36512264
[TBL] [Abstract][Full Text] [Related]
25. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
[TBL] [Abstract][Full Text] [Related]
26. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
27. Comparison of INSM1 immunostaining with established neuroendocrine markers synaptophysin and chromogranin A in over 14,000 neuroendocrine and non-neuroendocrine tumors.
Möller K; Uhlig R; Gorbokon N; Dum D; Menz A; Büscheck F; Luebke AM; Hube-Magg C; Hinsch A; Höflmayer D; Fraune C; Lebok P; Weidemann S; Lennartz M; Jacobsen F; Clauditz TS; Steurer S; Burandt E; Krech R; Krech T; Marx AH; Sauter G; Simon R; Bernreuther C; Minner S
Mol Cell Endocrinol; 2024 Feb; 581():112106. PubMed ID: 37951531
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
[TBL] [Abstract][Full Text] [Related]
29. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
31. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
32. Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin.
Juhlin CC; Zedenius J; Höög A
Endocr Pathol; 2020 Dec; 31(4):401-410. PubMed ID: 32813226
[TBL] [Abstract][Full Text] [Related]
33. Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany.
Grundmann N; Voigtländer S; Hakimhashemi A; Pape UF; Meyer M; Müller-Nordhorn J
Cancer Med; 2023 Oct; 12(19):19949-19958. PubMed ID: 37737059
[TBL] [Abstract][Full Text] [Related]
34. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis.
Ito T; Masui T; Komoto I; Doi R; Osamura RY; Sakurai A; Ikeda M; Takano K; Igarashi H; Shimatsu A; Nakamura K; Nakamoto Y; Hijioka S; Morita K; Ishikawa Y; Ohike N; Kasajima A; Kushima R; Kojima M; Sasano H; Hirano S; Mizuno N; Aoki T; Aoki T; Ohtsuka T; Okumura T; Kimura Y; Kudo A; Konishi T; Matsumoto I; Kobayashi N; Fujimori N; Honma Y; Morizane C; Uchino S; Horiuchi K; Yamasaki M; Matsubayashi J; Sato Y; Sekiguchi M; Abe S; Okusaka T; Kida M; Kimura W; Tanaka M; Majima Y; Jensen RT; Hirata K; Imamura M; Uemoto S
J Gastroenterol; 2021 Nov; 56(11):1033-1044. PubMed ID: 34586495
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy in Gastroenteropancreatic Neuroendocrine Neoplasia.
Popa Ilie IR; Georgescu CE
Neuroendocrinology; 2023; 113(2):262-278. PubMed ID: 34348340
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm.
Shi H; Jiang C; Zhang Q; Qi C; Yao H; Lin R
Diagn Pathol; 2020 Sep; 15(1):108. PubMed ID: 32917216
[TBL] [Abstract][Full Text] [Related]
37. State of the Art in Endoscopic Therapy for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Papaefthymiou A; Laskaratos FM; Koffas A; Manolakis A; Gkolfakis P; Coda S; Sodergren M; Suzuki N; Toumpanakis C
Curr Treat Options Oncol; 2022 Jul; 23(7):1014-1034. PubMed ID: 35511346
[TBL] [Abstract][Full Text] [Related]
38. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
Fang JM; Li J; Shi J
World J Gastroenterol; 2022 Mar; 28(10):1009-1023. PubMed ID: 35431496
[TBL] [Abstract][Full Text] [Related]
39. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Yin F; Wu ZH; Lai JP
World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
[TBL] [Abstract][Full Text] [Related]
40. The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms.
Schimmack S; Lawrence B; Svejda B; Alaimo D; Schmitz-Winnenthal H; Fischer L; Büchler MW; Kidd M; Modlin I
Cancer; 2012 May; 118(10):2763-75. PubMed ID: 21990041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
